{"nctId":"NCT03739528","briefTitle":"Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery","startDateStruct":{"date":"2018-09-03","type":"ACTUAL"},"conditions":["Cataract"],"count":808,"armGroups":[{"label":"Levofloxacin + Dexamethasone followed by dexamethasone","type":"EXPERIMENTAL","interventionNames":["Drug: Levofloxacin + dexamethasone followed by dexamethasone"]},{"label":"Tobramycin + dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tobramycin + Dexamethasone"]}],"interventions":[{"name":"Levofloxacin + dexamethasone followed by dexamethasone","otherNames":["Levofloxacin + dexamethasone followed by Maxidex"]},{"name":"Tobramycin + Dexamethasone","otherNames":["Tobradex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria prior to surgery:\n\n1. Signed written informed consent\n2. Male or female, age ≥40 years\n3. Scheduled senile or presenile cataract surgery\n4. Willing to interrupt the use of contact lenses for the entire duration of the study\n5. Able and willing to follow study procedures\n6. Female patients must be postmenopausal, surgically sterile or must agree to use an effective method of contraception\n\n   Inclusion criteria following surgery:\n7. Surgery completed without complications\n\nExclusion Criteria:\n\n1. Ocular conditions that at the discretion of the Investigator may interfere with the efficacy and/or safety evaluations\n2. Patients undergoing bilateral cataract surgery\n3. Patients under treatment with prostaglandin analogues or intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs\n4. Systemic diseases that may interfere with the results of the study\n5. Any condition that could interfere with correct instillation of eye drops\n6. Ocular surgery in the study eye (including laser surgery) in the 3 months before screening\n7. Monocular patients\n8. Visual Acuity \\< 20/80 of the contralateral eye measured as ETDRS or Snellen\n9. Contraindications to ocular treatment with Tobradex®, Maxidex® or levofloxacin/dexamethasone\n10. Hypersensitivity to the study product or its excipients\n11. Participation in other clinical studies within at least 5 half-lives of the Investigational Medicinal Product (IMP) used in the previous studies\n12. Pregnancy or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Without Signs of Anterior Chamber Inflammation","description":"The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS \\> - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"376","spread":null},{"groupId":"OG001","value":"373","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Endophthalmitis","description":"The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"393","spread":null},{"groupId":"OG001","value":"393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"391","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Without Signs of Anterior Ocular Chamber Inflammation","description":"Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null},{"groupId":"OG001","value":"393","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":null},{"groupId":"OG001","value":"302","spread":null}]},{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"341","spread":null}]},{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Conjunctival Hyperemia","description":"Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null},{"groupId":"OG001","value":"323","spread":null}]},{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"358","spread":null}]},{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"371","spread":null},{"groupId":"OG001","value":"375","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Ocular Symptoms Score (TOSS)","description":"The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.63"},{"groupId":"OG001","value":"0.37","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.67"},{"groupId":"OG001","value":"0.26","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.49"},{"groupId":"OG001","value":"0.17","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Ocular Pain/Discomfort: 4-point Scale","description":"Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"360","spread":null},{"groupId":"OG001","value":"361","spread":null}]},{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"366","spread":null},{"groupId":"OG001","value":"366","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"377","spread":null},{"groupId":"OG001","value":"373","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Therapy","description":"All rescue therapy used following cataract surgery is to be reported at all visits.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"392","spread":null},{"groupId":"OG001","value":"392","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Intraocular Pressure (IOP)","description":"IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.16","spread":"2.48"},{"groupId":"OG001","value":"15.12","spread":"2.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.26","spread":"2.73"},{"groupId":"OG001","value":"14.49","spread":"2.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.29","spread":"2.51"},{"groupId":"OG001","value":"14.45","spread":"3.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.45","spread":"2.65"},{"groupId":"OG001","value":"14.37","spread":"2.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Visual Acuity","description":"Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction.\n\nGenerally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision.\n\nLower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"0.23"},{"groupId":"OG001","value":"0.41","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.19"},{"groupId":"OG001","value":"0.89","spread":"0.17"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events","description":"Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Global Evaluation of Local Tolerability","description":"Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.21"},{"groupId":"OG001","value":"0.01","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.11"},{"groupId":"OG001","value":"0.03","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.15"},{"groupId":"OG001","value":"0.02","spread":"0.13"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Burning, Stinging, Blurred Vision","description":"Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.27"},{"groupId":"OG001","value":"0.09","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.24"},{"groupId":"OG001","value":"0.11","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.29"},{"groupId":"OG001","value":"0.07","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.23"},{"groupId":"OG001","value":"0.04","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.29"},{"groupId":"OG001","value":"0.07","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.26"},{"groupId":"OG001","value":"0.04","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.27"},{"groupId":"OG001","value":"0.05","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.25"},{"groupId":"OG001","value":"0.04","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.20"},{"groupId":"OG001","value":"0.01","spread":"0.11"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Assessment of Patient Diary (Compliance)","description":"Treatment compliance is derived from the number of instillations each day during the study treatment exposure","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"332","spread":null}]},{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"57","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":388},"commonTop":[]}}}